Exelixis Inc. (EXEL)
The price, the headline numbers and the latest news, in one place.
Exelixis Inc. (EXEL) Stock Price, Analysis & Data
| Bid | 51.64 |
| Market Cap | 13.49B |
| Revenue (ttm) | 2.44B |
| Net Income (ttm) | 860.62M |
| 0.42 | |
| 3.18 | |
| 17.12 | |
| 13.1 | |
| P/B (ttm) | 7.35 |
| P/S (ttm) | 5.54 |
| Earnings Date | Oct 27, 2026 |
| Ask | 54.46 |
| Volume | 1,486,394 |
| Avg. Volume (20D) | 2,569,698 |
| Open | 55.14 |
| Previous Close | 55.26 |
| Day's Range | 54.12 - 55.25 |
| 52-Week Range | 33.76 - 57.57 |
| Analyst | Buy |
| Price Target | 52 (-4.50%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About EXEL
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived f...
Financial Performance
In 2025, Exelixis's revenue was 2.32B, an increase of 6.98% compared to the previous year's 2.17B. Earnings were 782.57M, an increase of 50.13%.
Financial StatementsAnalyst Forecast
According to 17 analyst ratings, the average rating for EXEL stock is "Buy". The 12-month stock price forecast is 52, which is downside of 4.5% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $628.69M misses estimates by $0, with 10.63% YoY growth.
- EPS of 0.91 exceeds estimates by 0.04, with 21.33% YoY growth.
Analysts project revenue of ... Upgrade
